Global law firm Clifford Chance has advised Viking Global Investors, a global investment firm based in the United States, in acquiring a significant minority stake in Humaneva, a spin-off of NEUCA. Viking has also been granted a one-year option to increase its stake rateably in Humaneva, a provider of clinical trial solutions globally.
Neil Barlow and Carla Ruggero, private equity partners of Clifford Chance, led the Clifford Chance team based in the U.S. and Europe. They were assisted by associates Jack Weymer, Mark Sheehy and Sam Clinton-Davis, and law clerk Aljawharah Alsadoon.
The wider multi-practice team included:
- Corporate M&A: partner Wojciech Polz; counsel Tomasz Derda, Krzysztof Hajdamowicz, Tomasz Szymura; legal advisor Walkowicz; associates Alessia Saracino and Minji Shin
- Antitrust: partners Brian Conklin, Luciano Di Via and Dimitri Slobodenjuk; counsel Lauren Rackow and Ulrich A. Pfeffer; lawyers Maria Bazzini, Luca Borin, Alessandra Oliva; associates Santiago Roca Arribas, Kaia Pankey and Ross Mitchell Jablon; legal advisor Marta Michałek-Gervais
- Public Company: partner José Luis Zamarro, associate Octavio Canseco
- Tax: partner James Gouwar
- Employment and Incentives: partner Paul Koppel; senior associate Laura Conway; associates David Walsh; lawyer Martyna Proczek
- Regulatory: partner Megan Gordon and associates Holly Bauer and Martina Kneifel
_x000D_
_x000D_
_x000D_
_x000D_
_x000D_
_x000D_
“We’re extremely proud to have supported Viking close this transaction which is a significant deal that brings major private equity investment into clinical research,” Barlow said. “The planned geographical expansion and new initiatives are aimed at advancing improvements in the application of clinical treatment, which is clearly an important factor in delivering best-in-class healthcare solutions to people.”
